Market Overview

Therabiopharma (Japan Based Bio-Venture) Reports 10,000 Times Higher Curcumin Concentration in Bloodstream Clearly Demonstrates Strong Efficacies with/without Oxaliplatin in an Animal Study for Colon Cancer

Share:

Therabiopharma, a Japan based bio-venture, reports that CMG(Curcumin
Monoglucuronide) has proven:

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180821005346/en/

The image above demonstrates the efficacy of CMG for colon cancer and the synergetic effect with the ...

The image above demonstrates the efficacy of CMG for colon cancer and the synergetic effect with the simultaneous use with Oxaliplatin. (Graphic: Business Wire)

1. Same efficacy as Oxaliplatin for colon cancer without any adverse
effects observed in Oxaliplatin treatment (Oxaliplatin is one of most
frequently used colorectal cancer drugs worldwide).

2. Strong synergistic effect for colon cancer with Oxaliplatin.

3. Reduction of adverse effect of Oxaliplatin against hepatic functions.
This may alleviate the sinusoidal obstruction syndrome by
Therabiopharma's research for colon cancer (HCT-116) bearing nude mice.
(Figure
A)

CMG reduces the side effects of Oxaliplatin on liver functions, such as
increases in both ALT and AST, which are the indicators of liver damage.
(Figure
B)

At the same time, CMG clearly demonstrates its safety as:
No
reduction in body weight of mice during the entire period of this test.
No
reduction of number of white blood cells (WBC) and platelet (PLT) on Day
21.
(Figure C)

These novel and significant efficacies have been achieved by the unique
nature of the injectable CMG (curcumin monoglucuronide) which can
release 10,000 times higher amounts of the curcumin free form in the
bloodstream than normal curcumin powder intake orally (patent applied).
(Figure
D)

Therabiopharma Inc. focuses on the development of CMG as a drug for
various refractory cancers with/without other approved cancer drugs. In
particular, it has a strong focus for treatment/drug resistant cancers
with multiple mutations of genes.

Associate Prof. Kanai, PhD, MD, Graduate School of Medicine (Oncology),
Kyoto University and the scientific advisor of Therabiopharma said from
these findings and results, "The data shown here demonstrated that the
efficacy of curcumin monoglucuronide (CMG) is comparable to that of
oxaliplatin in mouse model. Of note, none of the toxicities associated
with cytotoxic anti-cancer drugs including myelosuppression (decrease of
blood cells), liver damage, and body weight loss were observed in CMG
arm, while they were evident in oxaliplatin arm. In daily clinical
practice, oxaliplatin is widely used as a key drug for cancer treatment
including colorectal, pancreatic, or gastric cancer in the world.
However, liver damage called "Sinusoidal Obstructive Syndrome (SOS)"
remains one of the serious adverse effects of oxaliplatin. SOS could
hamper the efficacy of oxaliplatin and sometimes causes symptoms derived
from liver failure. In this preclinical study, addition of CMG to
oxaliplatin showed the enhanced efficacy of oxaliplatin as well as
protective effect against oxaliplatin-induced liver damage. These data
support the idea that combination of CMG with oxaliplatin could be a
promising option in cancer treatment."

Prof. Kakeya, PhD, Graduate School of Pharmaceutical Science, Kyoto
University and the scientific advisor of Therabiopharma said for these
significant achievements on the newly developed CMG "This curcumin
monoglucuronide (CMG), a water-soluble prodrug of curcumin, could be
highly expected as an innovative synthetic anticancer drug based on the
natural product contained in turmeric."

T. Hashimoto, Therabiopharma CEO, said "These findings from the animal
test on CMG efficacy demonstrate CMG may play an important and
innovative role on the battle with cancers, particularly against the
drug/treatment resistant cancer in which the mutations of genes are
frequently observed.
CMG (curcumin monoglucuronide) has also proven
its ability to work with existing cancer drugs to materialize the
synergistic effect."

Therabiopharma Inc.
A new biotechnology venture company under
collaboration with Kyoto University:
Leveraging the potential power
of natural compounds/materials for medicine, diagnosis and
nutraceuticals to substantiate "healthy aging" world-wide.

View Comments and Join the Discussion!